Researchers from the University College Cork have described the neuroprotective effect of TMP-269, a class-IIa-specific histone deacetylase (HDAC) inhibitor in preclinical models of PD. Pan-inhibitors of HDAC have proven effective in models of Parkinson’s disease (PD) by preventing dopaminergic degeneration.